Antengene Corp., Ltd (HKG: 6996) has announced a significant price reduction for its drug Xpovio (selinexor) in China, cutting the cost by 37%. The new pricing for the 20mg*12 tablet box is RMB 14,135, and for the 20mg*16 tablet/box, it is RMB 18,649.67, down from the previous prices of RMB 22,435 and RMB 29,600, respectively. The company has advised relevant direct-to-patient pharmacies and retail sellers to adjust their retailing prices accordingly and to update online procurement prices to reflect this change.
Xpovio: The First and Only FDA-Approved Oral XPO1 Inhibitor
Discovered by US-based Karyopharm Therapeutics Inc. (Nasdaq:KPTI), Xpovio is the world’s first and only FDA-approved oral XPO1 inhibitor. The drug was conditionally approved in China in November 2021 for use in adult patients with relapsed/refractory multiple myeloma (R/R MM), specifically for those who have been previously treated with one other therapy.
Consideration for National Reimbursement Drug List (NRDL) Update
The drug is now set for consideration in this year’s National Reimbursement Drug List (NRDL) update, following the successful passage of the preliminary formal review process earlier this month. This potential inclusion in the NRDL could further improve patient access to Xpovio and reduce the financial burden for those battling R/R MM.-Fineline Info & Tech
